Medizinische Universität Graz - Research portal
Selected Publication:
Kulier, AH; Gombotz, H; Fuchs, G; Vuckovic, U; Metzler, H.
Subcutaneous recombinant human erythropoietin and autologous blood donation before coronary artery bypass surgery.
Anesth Analg. 1993; 76(1):102-106
Doi: 10.1213/00000539-199301000-00018
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Kulier Alexander
- Co-authors Med Uni Graz
- Fuchs Gottfried
- Metzler Helfried
- Posch Ursula
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Conventional therapies with recombinant human erythropoietin (rHuEPO) to sustain preoperative autologous blood collection entail high doses of the drug at short intervals. To evaluate the efficacy of a single weekly dose of rHuEPO for autologous blood collection, we randomly assigned 24 male patients scheduled for coronary artery bypass surgery to receive 400 IU/kg rHuEPO subcutaneously once a week or iron only. Patients were examined weekly and a total of up to 4 units of autologous blood were obtained if the hemoglobin level exceeded 12 g/dL. Patients receiving rHuEPO had consistently higher hemoglobin values than those receiving iron only (P < 0.001). Consequently, more autologous red cells were obtained from this group (776 +/- 49 mL vs 682 +/- 91 mL; P < 0.05). One patient receiving rHuEPO and eight in the control group required homologous blood at surgery (P < 0.01). These results suggest that 400 IU/kg rHuEPO administered subcutaneously once a week efficiently stimulates erythropoiesis and compensates the hemoglobin decrease after autologous blood donation.
- Find related publications in this database (using NLM MeSH Indexing)
- Blood Transfusion, Autologous -
- Coronary Artery Bypass -
- Erythropoiesis - drug effects
- Erythropoietin - pharmacology
- Humans - pharmacology
- Iron - pharmacology
- Male - pharmacology
- Middle Aged - pharmacology
- Prospective Studies - pharmacology
- Random Allocation - pharmacology